Clinical and pathologic aspects of spontaneous canine prostate carcinoma: A retrospective analysis of 76 cases

Cornell, Karen K.; Bostwick, David G.; Cooley, Dawn M.; Hall, Greg; Harvey, Hugh; Hendrick, Mattie J.; Pauli, Bendicht U.; Render, James A.; Stoica, George; Sweet, David C.; Waters, David J.

doi:10.1002/1097-0045(20001001)45:2<173::aid-pros12>3.0.co;2-r

Cited by 165 publications

(150 citation statements)

References 18 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…For development of CRAd agents, the human-mouse replication block has been particularly limiting, such that the available murine tumor models are of limited value vis-à-vis the ability to study replication-related toxicity and immunobiology. Alternatively, the availability of a range of canine models of human cancers (4,5,21,31) potentially provides a stringent model system for CRAd analysis. Our documentation of the ability of human adenovirus to replicate in canine target cells extends earlier observations with respect to human-canine cross-species replication (30) and raises the possibility of exploiting these canine models for full and comprehensive preclinical analysis of candidate CRAd agents designed for human virotherapy.…”

Section: Fig 3 Analysis Of Ad5 Replication In Human and Canine Cellmentioning

confidence: 99%

Productive Replication of Human Adenovirus Type 5 in Canine Cells

Ternovoi

Белоусова

et al. 2005

J Virol

View full text Add to dashboard Cite

Development of immunocompetent patient-like models that allow direct analysis of human adenovirus-based conditionally replicative adenoviruses (CRAds) would be beneficial for the advancement of these oncolytic agents. To this end, we explored the possibility of cross-species replication of human adenovirus type 5 (Ad5) in canine cells. With a panel of canine tumor cell lines of both epithelial and mesenchymal derivations, we demonstrate that human Ad5 can productively infect canine cells. Since the biological behavior and clinical presentation of certain dog tumors closely resemble those of their human counterparts, our results raise the possibility of exploiting canine models for preclinical analysis of candidate CRAd agents designed for human virotherapy.Conditionally replicative adenovirus (CRAd) agents represent a promising new therapeutic approach for cancer. This strategy is based on the application of an adenovirus engineered to selectively replicate in tumor targets (1, 3). This tumor-selective replication forms the functional basis of the antineoplastic effect achieved by direct target cell killing in a process termed oncolysis (1, 16). The exceptional promise of these agents has predicated their rapid transition to human phase I clinical trials whereby the overall safety of this approach has been validated (15,22,28). Nonetheless, the very limited indications of efficacy to this point have established the requirement for further design advances to enhance CRAd antitumor potency (11,15,20,23).Critical to the derivation of advanced-generation CRAds is the development of model systems capable of delineating key therapeutic indices. For CRAds, the fact that human adenoviruses can accomplish only abortive replication in murine targets (7-9, 17) has restricted the preclinical toxicity information that may be derived from SCID-xenograft model systems typically used for efficacy analysis. Further, these immunologically incompetent models cannot provide useful information with respect to CRAd immunobiology and vector-host interactions. On this basis, it is clear that there exists a field-wide need for immunocompetent syngeneic models for full analysis of candidate CRAd agents. Several recent reports have described model systems to achieve these goals. Hemminki et al. have exploited the availability of human-like canine models of cancer (31) for the evaluation of CRAd agents derived from canine adenoviruses (12,15,31). This approach potentially allows the study of vector-host interactions in an immunocompetent host in the context of a patient-like cancer model. CRAd constructs based on canine adenoviruses, however, may embody substantial biological differences from human adenovirus-based CRAds. Alternatively, an approach has been proposed whereby adapted murine cells permissive for limited human adenovirus replication are transplanted into an immunocompetent mouse host (10,29). Whereas this approach may allow direct analysis of human adenovirus-based CRAds in a murine system, this transplant model does not repre...

show abstract

Section: Fig 3 Analysis Of Ad5 Replication In Human and Canine Cellmentioning

confidence: 99%

Productive Replication of Human Adenovirus Type 5 in Canine Cells

Ternovoi

Белоусова

et al. 2005

J Virol

View full text Add to dashboard Cite

show abstract

“…This conserved growth regulation is further illustrated by the in vivo studies in which mouse RENCA cell macrobeads significantly extended the survival of canine patients with prostate adenocarcinoma (median survival of 177 days) as compared with no treatment (21-30 days; ref. 49) or to total prostatectomy or subtotal intracapsular prostatectomy [<50 days (n ¼ 10) and <2 weeks for 7/10 dogs, respectively; ref . 50].…”

Section: Discussionmentioning

confidence: 99%

Hydrophilic Agarose Macrobead Cultures Select for Outgrowth of Carcinoma Cell Populations That Can Restrict Tumor Growth

et al. 2011

Self Cite

View full text Add to dashboard Cite

Cancer cells and their associated tumors have long been considered to exhibit unregulated proliferation or growth. However, a substantial body of evidence indicates that tumor growth is subject to both positive and negative regulatory controls. Here, we describe a novel property of tumor growth regulation that is neither species nor tumor-type specific. This property, functionally a type of feedback control, is triggered by the encapsulation of neoplastic cells in a growth-restricting hydrogel composed of an agarose matrix with a second coating of agarose to form 6-to 8-mm diameter macrobeads. In a mouse cell model of renal adenocarcinoma (RENCA cells), this process resulted in selection for a stem cell-like subpopulation which together with at least one other cell subpopulation drove colony formation in the macrobeads. Cells in these colonies produced diffusible substances that markedly inhibited in vitro and in vivo proliferation of epithelial-derived tumor cells outside the macrobeads. RENCA cells in monolayer culture that were exposed to RENCA macrobead-conditioned media exhibited cell-cycle accumulation in S phase due to activation of a G 2 /M checkpoint. At least 10 proteins with known tumor suppression functions were identified by analysis of RENCA macrobead-conditioned media, the properties of which offer opportunities to further dissect the molecular basis for tumor growth control. More generally, macrobead culture may permit the isolation of cancer stem cells and other cells of the stem cell niche, perhaps providing strategies to define more effective biologically based clinical approaches to treat neoplastic disease. Cancer Res; 71(3); 725-35. Ó2011 AACR.

show abstract

“…Adenocarcinoma, transitional cell carcinoma and undifferentiated carcinoma are the most common histological type [5], but the precise cell of origin in dog is not know. The incidence of prostatic carcinoma (PCA) in dogs is low (0.2% -0.6%) in necroscopy studies [6], but it shares several of the features of the disease in humans [7].…”

Section: Introductionmentioning

confidence: 99%

Canine Prostate Carcinoma: Four Clinical Cases in Sexually Intact and Neutered Dogs

Bigliardi¹,

Bresciani²,

Cantoni³

et al. 2012

OJU

View full text Add to dashboard Cite

Prostate cancer is one of the most important malignancies in men. In old men the frequency of prostate cancer at necroscopy has been reported to exceed 40%. Dogs are the only large mammals other than humans with a significant incidence of spontaneous prostate cancer. Adenocarcinoma, transitional cell carcinoma and undifferentiated carcinoma are the most common histological type but the precise cell of origin in dog is not known. The incidence of prostatic carcinoma in dogs is low (0.2% -0.6%). Prostatic carcinomas occur in sexually intact and neutered dogs and the risk increase in castrated dogs associated to pulmonary and bone metastases. The castration does not initiate the development of prostatic carcinoma in dog but does favour tumour progression. In men the early stage detection of prostate cancer can offer various therapies as radical prostatectomy, radial therapy, thermal ablation, anti-androgen therapy, chemotherapy. In dogs the diagnosis is often in advanced stage of the cancer and the survival time for dogs with prostate cancer is poor. The median time reported is 30 days after diagnosis. In this study we reported three cases of prostatic carcinoma in intact sexually dogs and one in a neutered dog. The sexually intact subjects were older (mean age = 10.5 years) and they had prostatic adenocarcinoma (PCA). The interval between castration and onset of prostatic problems was 3 years. All the dogs showed dysuria, macroscopic hematuria, dyschezia and ataxia. All dogs have been euthanized in order to relieve pain and suffering.

show abstract

Clinical and pathologic aspects of spontaneous canine prostate carcinoma: A retrospective analysis of 76 cases

Cited by 165 publications

References 18 publications

Productive Replication of Human Adenovirus Type 5 in Canine Cells

Productive Replication of Human Adenovirus Type 5 in Canine Cells

Hydrophilic Agarose Macrobead Cultures Select for Outgrowth of Carcinoma Cell Populations That Can Restrict Tumor Growth

Canine Prostate Carcinoma: Four Clinical Cases in Sexually Intact and Neutered Dogs

Contact Info

Product

Resources

About